News stories about Repligen (NASDAQ:RGEN) have trended somewhat positive on Friday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Repligen earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 48.2486796364165 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
RGEN has been the topic of a number of recent research reports. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday, January 19th. Citigroup started coverage on Repligen in a research report on Friday, December 8th. They set a “buy” rating and a $45.00 price target on the stock. Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 24th. Finally, TheStreet upgraded Repligen from a “c” rating to a “b-” rating in a research note on Tuesday, March 13th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Repligen has a consensus rating of “Buy” and an average price target of $44.38.
RGEN remained flat at $$36.47 on Friday. The company’s stock had a trading volume of 273,680 shares, compared to its average volume of 269,107. The firm has a market cap of $1,571.36, a PE ratio of 52.86, a PEG ratio of 2.41 and a beta of 0.87. The company has a current ratio of 9.63, a quick ratio of 8.08 and a debt-to-equity ratio of 0.17. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $46.81.
In related news, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the completion of the sale, the chief executive officer now directly owns 83,613 shares of the company’s stock, valued at $3,005,887.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 4,696 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the sale, the director now directly owns 9,700 shares of the company’s stock, valued at $350,752. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Repligen (RGEN) Stock Price” was originally published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/2018/04/06/repligen-rgen-receives-daily-media-sentiment-rating-of-0-22/2037672.html.
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.